Although BCR–ABL TKIs have already displayed excellent efficacy in the treatment of CML, patients need extended or even lifetime TKI therapy, which increases risk of complications and economic burden. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.